1. Scrip
  2. >>Business
  3. >>Strategy

Basilea Bids Farewell To Oncology To Focus On Anti-Infectives

Puts Faith In US Approval Of Antibiotic Zevtera

 
• By Kevin Grogan

Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.

severing ties and boycott concept
Basilea cutting off its cancer assets • Source: Archive

After a strategic review, Basilea Pharmaceutica Ltd. has decided to exit the oncology space and concentrate on becoming a leading anti-infectives company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business